Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 25 versus ZANTAC IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 25 versus ZANTAC IN PLASTIC CONTAINER.
ZANTAC 25 vs ZANTAC IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells, reducing both basal and stimulated acid production.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Ranitidine 150 mg orally twice daily or 50 mg intravenously every 6-8 hours.
150 mg orally twice daily or 50 mg intravenously every 6 to 8 hours.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.0 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 6-8 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2.5–3 hours; prolonged to 4–5 hours in elderly or moderate renal impairment; accumulates in severe renal failure (CrCl <10 mL/min).
Renal: 70% unchanged via tubular secretion; fecal: 30% as metabolites (N-oxide, S-oxide, desmethyl).
Renal: 70% (unchanged drug); Hepatic metabolism: 30% (minor N-oxide, S-oxide, and desmethyl metabolites); Biliary/fecal: negligible.
Category C
Category C
H2 Antagonist
H2 Antagonist